관련문헌 등
·Harrison's Principles of Internal Medicine, 20e > Chapter 54: Skin Manifestations of Internal Disease > HYPOPIGMENTATION
·Fitzpatrick's Dermatology in General Medicine, 8e 2012 > Chapter 74. Vitiligo > Treatment
·Clinical Dermatology Sixth Edition 2016 > Chapter 19. Light-related diseases and disorders of pigmentation > DISORDERS OF HYPOPIGMENTATION > Vitiligo
·A. Taieb, et al. Guidelines for the Management of Vitiligo. The European Dermatology Forum Consensus, 2012 British Association of Dermatologists 2013 168, pp5？19
·Naoki OISO, et al. Guidelines for the diagnosis and treatment of vitiligo in Japan, Journal of Dermatology 2013; 40: 344？354.
·A. Wollenberg, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I, JEADV 2018, 32, 657？682.
·Ichiro Katayama, et al. Japanese guidelines for atopic dermatitis 2017*, Allergology International 66 (2017) 230e247
·Bae JM, et al. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol. 2016 May;74(5):907-15.
·Bapur Erduran F, et al. Comparison of the efficacy of 308-nm excimer lamp monotherapy with topical tacrolimus or clobetasol 17-propionate combination therapies in localized vitiligo. Photodermatol Photoimmunol Photomed. 2016 Sep;32(5-6):247-253.
·Sisti A, et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. An Bras Dermatol. 2016 Apr;91(2):187-95.
·Park OJ, et al. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. Clin Exp Dermatol. 2016 Apr;41(3):236-41.
·Cavalie M, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015 Apr;135(4):970-4.
·Ho N, et al. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. Br J Dermatol. 2011 Sep;165(3):626-32.
·Majid I, et al. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed. 2010 Oct;26(5):230-4.
·de Menezes AF, et al. Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review. Pediatr Dermatol. 2017 Jan;34(1):13-24.
·Dang YP, et al. Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis. Dermatol Ther. 2016 Mar-Apr;29(2):126-33.
·Roy P, et al. Effectiveness of Topical Corticosteroid, Topical Calcineurin Inhibitors and Combination of Them in the Treatment of Vitiligo. Mymensingh Med J. 2016 Oct;25(4):620-627.
·Dayal S, et al. Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy. Pediatr Dermatol. 2016 Nov;33(6):646-651.
·Njoo MD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol. 1998 Dec;134(12):1532-40.
·Lepe V, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003 May;139(5):581-5.
·Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol. 2009 May-Jun;26(3):286-91.
·Shim WH, et al. A pilot study of 1% pimecrolimus cream for the treatment of childhood segmental vitiligo. Ann Dermatol. 2013 May;25(2):168-72.
·Kose O, et al. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010 May;21(3):133-9.
·Dawid M, et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006 Nov;4(11):942-6.
·Kumaran MS, et al. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006 Mar;20(3):269-73.
·Esfandiarpour I, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20(1):14-8.
·Kathuria S, et al. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol. 2012 Jan-Feb;78(1):68-73.
·Westerhof W, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999 Sep;135(9):1061-6.
·Coskun B, et al. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005 Mar-Apr;15(2):88-91.
·Jordi Castellsague, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation ？ JOELLE study). Clinical Epidemiology 2018:10 299？310.
·David J, et al. Association Between Malignancy and Topical Use of Pimecrolimus. JAMA Dermatology Published online February 18, 2015.
·S. C. S. Cai, et al. Topical calcineurin inhibitors in eczema and cancer association: A cohort study. JOURNAL OF DERMATOLOGICAL TREATMENT, 2016.